Comparing the current results to its competitors, Insight Molecular Diagnostics Inc reported Revenue decrease in the 2 quarter 2026 year on year by -53.86 %, despite the revenue increase by the most of its competitors of 23.9 %, recorded in the same quarter.
Insight Molecular Diagnostics Inc 's Comment on Competition and Industry Peers
The company focuses on evidence generation, innovation, operational flexibility, and regulatory strategy as key differentiators from its competitors. It has developed and commercialized GraftAssureCore, GraftAssureIQ, and GraftAssureDx. Medicare reimbursement, particularly through the Centers for Medicare & Medicaid Services (CMS) and its Medicare Administrative Contractors (MACs), which develop local coverage determinations (LCDs), is a critical factor for the company's diagnostic tests.
Oncotelic Therapeutics Inc is a biotechnology company that focuses on developing and commercializing novel therapeutics for the treatment of cancer. Their business model revolves around conducting research to develop innovative drugs and therapies, and subsequently bringing those products to market to generate revenue and improve patient outcomes in cancer treatment.
Natera Inc operates as a genetic testing company that provides non-invasive screening and diagnostic tests for reproductive health, oncology, and organ transplantation. The company's business model is built around offering cost-effective and accurate genetic testing solutions for both patients and healthcare providers. Natera primarily generates revenue by selling its proprietary tests and associated analysis services to customers, including hospitals, laboratories, and physicians.
Myriad Genetics Inc's business model revolves around providing molecular diagnostic testing services and developing innovative precision medicine solutions that help identify and personalize treatment options for patients across various medical specialties.
Guardant Health Inc's business model revolves around providing advanced genomic testing services for cancer patients. It specializes in developing liquid biopsy tests that analyze circulating tumor DNA (ctDNA) in the blood. These tests help in early cancer detection, treatment selection, and monitoring of cancer progression. Guardant Health Inc collaborates with healthcare providers, pharmaceutical companies, and researchers to provide these innovative tests and contribute to the advancement of precision medicine in oncology.
Sources:
Insight Molecular Diagnostics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Insight Molecular Diagnostics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
